ALLOPURINOL (allopurinol) by Teva is xanthine oxidase inhibitors [moa]. First approved in 1984.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
Allopurinol is an oral xanthine oxidase inhibitor approved in 1984 for managing hyperuricemia and gout by reducing uric acid production. It works by inhibiting the enzyme xanthine oxidase, which catalyzes the final steps of uric acid synthesis. This generic small molecule is a foundational therapy in urate-lowering treatment.
As a mature generic with approaching LOE, the brand team is focused on defending market share and optimizing established manufacturing; expect smaller commercial teams and cost-control emphasis rather than growth-stage investment.
Xanthine Oxidase Inhibitors
Xanthine Oxidase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Worked on ALLOPURINOL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on allopurinol offers limited career growth given its mature, generic status and approaching end-of-life for branded offerings. Roles available are primarily in operations, safety, and cost management rather than commercial or clinical innovation.